Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-10-03 am EDT
1319.60 GBX   +1.06%
10/03GSK : Deutsche Bank reiterates its Neutral rating
MD
09/29Haleon Launches Exchange Offers for Seven Series of Notes
MT
09/29Central banks are here to save the day
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

08/12/2022 | 04:24am EDT
FILE PHOTO: Zantac heartburn pills are seen in this picture illustration

LONDON (Reuters) - Shares in GSK, Sanofi <SASY.PA and Haleon began to stabilise on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.

The companies' share prices had fallen sharply this week on investor concern about the litigation over potential cancer-causing impurities that prompted the drug's withdrawal from markets in 2019 and 2020. The first U.S. trial is expected to start this month.

(Reporting by Natalie Grover in London; Editing by David Goodman)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 1.06% 1319.6 Delayed Quote.-19.71%
HALEON PLC -3.03% 270.8 Delayed Quote.0.00%
SANOFI 1.79% 79.8 Real-time Quote.-9.91%
All news about GSK PLC
10/03GSK : Deutsche Bank reiterates its Neutral rating
MD
09/29Haleon Launches Exchange Offers for Seven Series of Notes
MT
09/29Central banks are here to save the day
MS
09/29Ooddo BHF Upgrades GSK to Outperform from Neutral, Lifts PT
MT
09/29Analyst recommendations: Alphabet, Direct Line, Endava, GSK, Vi..
MS
09/29Nestle CEO: I'm not a 'mega deal' maker
RE
09/28Designer Daniel Lee replaces Riccardo Tisci at Burberry
RE
09/27GSK : Gets a Neutral rating from Barclays
MD
09/27Iain Mackay, Chief Financial Officer, to retire from GSK, Julie Brown appointed as succ..
AQ
09/26Health Care Down as Investors Flee Defensive Sectors -- Health Care Roundup
DJ
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 28 235 M 31 919 M 31 919 M
Net income 2022 4 477 M 5 061 M 5 061 M
Net Debt 2022 13 727 M 15 518 M 15 518 M
P/E ratio 2022 11,5x
Yield 2022 4,60%
Capitalization 53 422 M 60 392 M 60 392 M
EV / Sales 2022 2,38x
EV / Sales 2023 2,26x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 319,60 GBX
Average target price 1 835,51 GBX
Spread / Average Target 39,1%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-19.71%60 392
JOHNSON & JOHNSON-4.60%429 503
ELI LILLY AND COMPANY17.06%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.25%245 597
ABBVIE INC.-0.88%237 296